# Batch 16 Partial-1 Multi-Module / Note / PDF Reaudit Report

Generated: `2026-06-22`  
Coverage: the next 30 confirmed-core records in flat master-list row order after `ASD-0516`: `ASD-0517`, `ASD-0518`, `ASD-0519`, `ASD-0520`, `ASD-0521`, `ASD-0522`, `ASD-0523`, `ASD-0524`, `ASD-0525`, `ASD-0526`, `ASD-0528`, `ASD-0529`, `ASD-0530`, `ASD-0531`, `ASD-0535`, `ASD-0536`, `ASD-0537`, `ASD-0538`, `ASD-0539`, `ASD-0540`, `ASD-0541`, `ASD-0542`, `ASD-0543`, `ASD-0544`, `ASD-0545`, `ASD-0547`, `ASD-0548`, `ASD-0549`, `ASD-0552`, and `ASD-0553`.  
Mode: `Batch 16 partial-1`; this round followed the plan-defined structure: `Evidence-Agent-A/B/C` for read-only evidence collection, `Classification-Reviewer` for independent adjudication, `Writeback-Agent-1/2/3` for disjoint note writeback on the approved landing subset, and `Main Controller` for the only master/progress/report closeout.

## 1. 本次收口结果

- 本次直接落地 `6` 篇：
  - `ASD-0521`
  - `ASD-0522`
  - `ASD-0540`
  - `ASD-0548`
  - `ASD-0549`
  - `ASD-0552`
- 本次已审但保守挂起 `24` 篇：
  - `ASD-0517`
  - `ASD-0518`
  - `ASD-0519`
  - `ASD-0520`
  - `ASD-0523`
  - `ASD-0524`
  - `ASD-0525`
  - `ASD-0526`
  - `ASD-0528`
  - `ASD-0529`
  - `ASD-0530`
  - `ASD-0531`
  - `ASD-0535`
  - `ASD-0536`
  - `ASD-0537`
  - `ASD-0538`
  - `ASD-0539`
  - `ASD-0541`
  - `ASD-0542`
  - `ASD-0543`
  - `ASD-0544`
  - `ASD-0545`
  - `ASD-0547`
  - `ASD-0553`
- 本次没有新增 `safety_skip`；所有未落地原因仍是 `source_limited` / access limits，而不是安全性阻断。

## 2. 结果概览

- landed notes updated: `6`
- landed master rows updated: `6`
- progress rows added this round: `30`
- `closed=yes` added: `6`
- `closed=no` added: `24`
- newly synced shared-note-path cases handled without ownership collision:
  - `ASD-0521` with shared note `Notes/06_Life_Sciences/Qu_2025_CRISPR_GPT.md`
  - `ASD-0522` with shared note `Notes/04_Materials_Science/Mandal_2024_AILA_Autonomous_Microscopy.md`
  - `ASD-0540` with shared note `Notes/07_Medical_and_Health_Sciences/Ghareeb_2025_Robin.md`

## 3. Landed Record-Level Outcomes

| ID | Final modules or bucket | PDF / source status | Closeout note |
|---|---|---|---|
| ASD-0521 | `06` | archived local full text | `CRISPR-GPT` stayed a stable life-science record; local archived full text was rechecked and the shared note was refreshed without changing the adjudicated module set |
| ASD-0522 | `04;09` | archived local full text | AFM sample-characterization evidence keeps `04`, while scientific-instrument operation keeps `09`; note wording now explicitly separates filing convenience from classification authority |
| ASD-0540 | `06;07` | archived local arXiv full text | Robin remains filed under `07`, but the landed note now makes `06;07` authoritative and marks any older single-module wording as superseded |
| ASD-0548 | `06;07` | PMC full text checked | OpenScientist keeps the biomedical `07` primary filing while preserving independent omics / cellular `06` coverage; no local PDF was added this round |
| ASD-0549 | `02` | arXiv preprint + DOI metadata checked | DeepInflation is now synchronized to the landed `02` reading; legacy `02.01` remains only as a topical hint, not an extra supported module |
| ASD-0552 | `07` | PMC full text checked | Alzheimer drug-combination hypothesis generation with `in vitro` validation remains a secure single-module `07` landing |

## 4. Conservative Carry-Forward Logic

本轮没有把其余 `24` 篇强行写进 master，原因不是它们一定错，而是当前证据层级还不足以支持“主控落地 + note 改写 + master 改写”的完整 closeout。主要分成四类：

- local-note / abstract / metadata lead-only：
  - `ASD-0517`, `ASD-0518`, `ASD-0523`, `ASD-0524`, `ASD-0525`, `ASD-0526`, `ASD-0528`, `ASD-0529`, `ASD-0530`, `ASD-0531`, `ASD-0535`, `ASD-0536`, `ASD-0537`, `ASD-0538`, `ASD-0539`, `ASD-0541`, `ASD-0542`, `ASD-0543`, `ASD-0544`, `ASD-0545`, `ASD-0547`, `ASD-0553`
- confirmed-core / Agent-strength still weak enough that this round should not overstate certainty：
  - `ASD-0519`
  - `ASD-0520`
- explicit `01.04` hold retained until stronger object-level full-text evidence appears：
  - `ASD-0530`
  - `ASD-0541`
  - `ASD-0553`

本轮将这 `24` 篇全部登记进 progress，但统一标为 `closed=no`，这样下一轮不会重复从 `ASD-0517` 起步，同时也不会把这些 source-limited decisions 冒充成已完成 closeout。

## 5. Shared Note-Path Handling

本批三个共享 note 风险点都按 plan 的 note-file ownership 规则处理：

- `ASD-0521` / `ASD-0081` 共用 `Qu_2025_CRISPR_GPT.md`
  - 本轮只补 `2026-06-22 Batch16 full-reaudit check` 与第一手来源同步，不重写旧 paper 的事实描述。
- `ASD-0522` / `ASD-0026` 共用 `Mandal_2024_AILA_Autonomous_Microscopy.md`
  - 本轮只显式重申已裁决的 `04;09`，并说明 note path 只是 filing convenience。
- `ASD-0540` / `ASD-0083` 共用 `Ghareeb_2025_Robin.md`
  - 本轮只把 landed `06;07` 裁决写成 authoritative wording，并标记旧的单模块 `07` 语句为 superseded。

没有发生双写同一 note 的 ownership 冲突。

## 6. Multi-Agent Audit Trace

- `Evidence-Agent-A/B/C`
  - 完成了本批 30 篇的连续切片只读取证，输出保存在 `%TEMP%\\asd_round_batch16_evidence\\`.
- `Classification-Reviewer`
  - 在只读 merged evidence packs 上返回了本批 adjudication，并明确给出 high-confidence direct landings、conservative holds、以及 no safety-skip additions。
- `Writeback-Agent-1/2/3`
  - `Writeback-Agent-2` 和 `Writeback-Agent-3` 返回了标准 completion packet。
  - `Writeback-Agent-1` 没有留下单独 `writeback_1.txt`，但其两篇 owned note 已实际写入 worktree，主控已通过 `git diff` 核实：
    - `Qu_2025_CRISPR_GPT.md`
    - `Roberts_2026_OpenScientist_Biomedical_Discovery.md`
- `Main Controller`
  - 审阅了 6 个 landed note diff
  - 确认 shared-note ownership 未冲突
  - 更新 `agent_master_paper_list.md`
  - 更新 `multi_module_note_pdf_full_reaudit_progress_451_2026-06-21.md`
  - 写入本 partial report

## 7. 本次后统计变化

- confirmed included-and-classified record count remains `451`
- expanded module assignment count remains `556`
- independent `01.04` bucket count remains `11`
- progress tracker reviewed-row count: `163 -> 193`
- progress tracker `closed=yes`: `158 -> 164`
- progress tracker `closed=no`: `5 -> 29`
- progress-unregistered remainder after this partial: `258`
- safety-open queue remains unchanged; no new safety case was added beyond the previously carried `ASD-0054`

## 8. Next Step

因为本批 30 篇已经全部写入 progress：

- 下一个 flat master-order 起点应移到 `ASD-0553` 之后的下一条 confirmed-core 未登记记录。
- 按当前 master 可见顺序，下一条候选起点是 `ASD-0554`。
- 同时，`closed=no` 队列中新增的 `24` 篇应保留为后续 full-text / stronger-source follow-up queue，而不是重新当作“未处理”记录。
